{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:40:42Z","timestamp":1792568442960,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06242-1","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:35:33Z","timestamp":1789461333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe perioperative immune-related adverse events requiring intensive care in patients with gastric cancer: a case series"],"prefix":"10.1186","volume":"20","author":[{"given":"Hiroshi","family":"Hadatsuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Takuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuKi","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurina","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"6242_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku N, Ryu M, Kato K, et al. Safety and efficacy of Nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30:250\u20138.","journal-title":"Ann Oncol"},{"key":"6242_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"Y Janjigian","year":"2021","unstructured":"Janjigian Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"6242_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13613-020-00761-w","volume":"10","author":"A Joseph","year":"2020","unstructured":"Joseph A, Simonaggio A, Stoclin A, et al. Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. Ann Intensive Care. 2020;10:143.","journal-title":"Ann Intensive Care"},{"key":"6242_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13613-023-01122-z","volume":"13","author":"A Toffart","year":"2023","unstructured":"Toffart A, Meert A, Wallet F, et al. ICU admission for solid cancer patients treated with immune checkpoint inhibitors. Ann Intensive Care. 2023;13:39.","journal-title":"Ann Intensive Care"},{"key":"6242_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7302","volume":"13","author":"L Lin","year":"2024","unstructured":"Lin L, Houwink A, Dieren JV, et al. Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors. Cancer Med. 2024;13: e7302.","journal-title":"Cancer Med"},{"key":"6242_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cei.13424","volume":"200","author":"Z Quandt","year":"2020","unstructured":"Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020;200:131\u201340.","journal-title":"Clin Exp Immunol"},{"key":"6242_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/jdi.13807","volume":"12","author":"S Hatayama","year":"2022","unstructured":"Hatayama S, Kodama S, Kawana Y, et al. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment. J Diabetes Investig. 2022;12:1458\u201360.","journal-title":"J Diabetes Investig"},{"issue":"8","key":"6242_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","volume":"158","author":"M Asdourian","year":"2022","unstructured":"Asdourian M, Shah N, Jacoby T, et al. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer. JAMA Dermatol. 2022;158(8):933\u201341.","journal-title":"JAMA Dermatol"},{"key":"6242_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","volume":"23","author":"A Lopez","year":"2018","unstructured":"Lopez A, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist. 2018;23:1119\u201326.","journal-title":"Oncologist"},{"key":"6242_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588582","volume":"11","author":"C Sadik","year":"2020","unstructured":"Sadik C, Langan E, Gutzmer R, et al. Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers. Front Immunol. 2020;11: 588582.","journal-title":"Front Immunol"},{"key":"6242_CR11","doi-asserted-by":"publisher","first-page":"oyae186","DOI":"10.1093\/oncolo\/oyae186","volume":"30","author":"M Buckley","year":"2025","unstructured":"Buckley M, Warner A, Brahmer J, et al. Immune-related encephalitis after immune checkpoint inhibitor therapy. Oncologist. 2025;30:oyae186.","journal-title":"Oncologist"},{"key":"6242_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13256-018-1786-9","volume":"12","author":"J Kopecky","year":"2018","unstructured":"Kopecky J, Kubecek O, Geryk T, et al. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep. 2018;12:262.","journal-title":"J Med Case Rep"},{"issue":"5","key":"6242_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1073274817729069","volume":"24","author":"K Richard","year":"2017","unstructured":"Richard K, Weslow J, Porcella S, et al. A case report of steroid responsive nivolumab-induced encephalitis. Cancer Control. 2017;24(5):1\u20133.","journal-title":"Cancer Control"},{"issue":"2","key":"6242_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/diseases10020024","volume":"10","author":"D Kaakour","year":"2022","unstructured":"Kaakour D, Ward G, Dayyani F. Early adoption of checkpoint inhibitors in patients with metastatic gastric adenocarcinoma-a case series of non-operative long-term survivors. Diseases. 2022;10(2):24.","journal-title":"Diseases"},{"issue":"12","key":"6242_CR15","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"D Wang","year":"2018","unstructured":"Wang D, Salem J, Cohen J, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"6242_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","volume":"8","author":"E Nadelmann","year":"2022","unstructured":"Nadelmann E, Yeh J, Chen S. Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review. JAMA Oncol. 2022;8(1):130\u20138.","journal-title":"JAMA Oncol"},{"key":"6242_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.908558","volume":"13","author":"P Dai","year":"2022","unstructured":"Dai P, Rao X, Zhang X, et al. Case report: complete remission of a patient with metastatic gastric cancer treated with nivolumab combined with chemotherapy after palliative surgery. Front Immunol. 2022;13: 908558.","journal-title":"Front Immunol"},{"key":"6242_CR18","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.21873\/anticanres.15626","volume":"42","author":"H Suematsu","year":"2022","unstructured":"Suematsu H, Kano K, Yamada T, et al. Prognostic impact of immune-related adverse events in gastric cancer patients treated with nivolumab. Anticancer Res. 2022;42:1535\u201340.","journal-title":"Anticancer Res"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06242-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06242-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06242-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:02:48Z","timestamp":1792566168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06242-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6242"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06242-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As this is a retrospective case series, ethical approval was not required, and patient consent was obtained.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patients or their legal guardians for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"643"}}